Addex reprices 200K options to $0.032 strike

Addex Therapeutics adjusted an executive’s option and deferred-share strike prices to $0.032 per share without changing the number of units or other terms.

Rhea-AI Filing Summary

Addex Therapeutics Ltd. (ADXN) reported administrative equity-compensation changes for officer Mikhail Kalinichev on September 2, 2026. The company recorded the disposition to the issuer and regrant of 200,000 stock options with the exercise price reduced from $0.062 to $0.032 per share, and reflected a related repricing for 306,765 shares previously acquired under a deferred strike price payment plan. Footnotes state all other option and plan terms remain unchanged and that the transactions were exempt under specified Exchange Act rules.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Kalinichev Mikhail

Role HEAD OF TRANSLATIONAL SCIENCE

Type	Security	Shares	Price	Value
Disposition	Stock-option (Right to Buy) F3, F2	200,000	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) F3, F2	200,000	$0.00	$0.00
Disposition	Common Stock F1	306,765	$0.00	$0.00
Grant/Award	Common Stock F1	306,765	$0.00	$0.00

Holdings After Transaction: Stock-option (Right to Buy) — 200,000 contracts (Direct); Common Stock — 306,765 shares (Direct)

Footnotes (3)

1. F1. Represents 306,765 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 179,171 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 127,594 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $ 1.2296 per CHF 1.00 as of September 2, 2026.
2. F2. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
3. F3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

Key Figures

Options repriced: 200,000 options Old option exercise price: $0.062 per share New option exercise price: $0.032 per share +3 more

6 metrics

Options repriced 200,000 options Stock-option transactions dated September 2, 2026

Old option exercise price $0.062 per share Exercise price on disposed stock options before repricing

New option exercise price $0.032 per share Exercise price on granted stock options after Remuneration Committee decision

Shares under deferred strike plan 306,765 shares Common stock acquired under deferred strike price payment plan

Exchange rate used $1.2296 per CHF 1.00 Conversion rate to report strike prices in U.S. dollars as of September 2, 2026

Option and plan repricing date September 2, 2026 Date Remuneration Committee’s repricing decision was implemented

Key Terms

deferred strike price payment plan, exercise price, Rule 16b-6(d), Rule 16b-3

4 terms

deferred strike price payment plan financial

"shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares... under the deferred strike price payment plan"

exercise price financial

"the exercise price of the options were repriced to $0.032"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Rule 16b-6(d) regulatory

"Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"

Rule 16b-3 regulatory

"Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

FAQ

What insider equity change did ADXN report for Mikhail Kalinichev?

Addex Therapeutics reported that on September 2, 2026, Mikhail Kalinichev’s stock options and deferred strike plan units were repriced to $0.032 per share, with the number of 200,000 options and 306,765 shares unchanged and all other terms remaining the same.

How many Addex Therapeutics (ADXN) options were affected in this Form 4?

The filing shows 200,000 stock options in a pair of transactions: a disposition of 200,000 options with a $0.062 exercise price and a grant of 200,000 options with a $0.032 exercise price, both dated September 2, 2026.

What happened to the 306,765 Addex Therapeutics (ADXN) common shares mentioned in the footnote?

The footnote states that 306,765 common shares, previously acquired on the SIX Swiss Exchange under a deferred strike price payment plan, had their strike price reduced to $0.032 per share on September 2, 2026, while all other plan terms remained unchanged.

Were the ADXN insider transactions made under a Rule 10b5-1 trading plan?

No. The document-level checkbox indicates no Rule 10b5-1 trading plan, and the footnotes describe the changes as repricing decisions by the Remuneration Committee, not pre-arranged trading under such a plan.

Did the ADXN officer buy or sell shares on the open market in this Form 4?

No open-market purchases or sales are reported. The non-derivative entries show 306,765 common shares as dispositions and acquisitions to and from the issuer, reflecting repricing within a deferred strike price payment plan rather than market trades.

What exchange rate did Addex Therapeutics use to report the option prices in USD?

The footnotes state that the strike prices are reported in U.S. dollars using an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026, converting from Swiss francs for disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:10 PM Accepted by SEC EDGAR 09/04/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalinichev Mikhail

(Last) (First) (Middle)

CHEMIN DES MINES 9

(Street)

GENEVA CH-1202

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	HEAD OF TRANSLATIONAL SCIENCE

2a. Foreign Trading Symbol
[[ADXN]]

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		D(1)		306,765	D	$0(1)	0	D
Common Stock	09/02/2026		A(1)		306,765	A	$0(1)	306,765	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock-option (Right to Buy)	$0.062(3)	09/02/2026		D(2)			200,000	01/08/2024	01/07/2034	Common Stock	200,000	$0	0	D
Stock-option (Right to Buy)	$0.032(3)	09/02/2026		A(2)		200,000		01/08/2024	01/07/2034	Common Stock	200,000	$0	200,000	D

Explanation of Responses:

1. Represents 306,765 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 179,171 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 127,594 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $ 1.2296 per CHF 1.00 as of September 2, 2026.

2. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.

3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

	/s/ Lenaic Nathanael Teyssedou by power of attorney	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)